



TATA POWER DELHI DISTRIBUTION LIMITED
A Tata Power and Delhi Government Joint Venture
TATAPOWER-DDL Regd. Office: NDPL House, Hudson Lines, Kingsway Camp, Delhi-110 009
CIN No. U40108DL2001PLC111526, Website: tatapower-ddl.com

NOTICE INVITING TENDERS
Nov 14, 2025

TATA Power-DDL invites tenders as per following details:
As per the guidelines issued by Government of India & approval given by Hon'ble DERC, Tata Power Delhi Distribution Limited (Tata Power-DDL) is inviting Long Term Bids for Procurement of FDRE Power with ESS as per details provided in table below:

Tender Enquiry No. Work Description	EMD (Rs.)	Availability of Bid Document	Last Date & Time of RFS/Bid Submission
TPDDL/PMG/Tender/FDRE-Power/ Purchase-2025-26/01 Notice inviting bids for procurement of 200 MW FDRE Power with ESS with a Green shoe option of contracting additional 200 MW from ISTS connected RE Power Projects in India through competitive bidding process.	As per the tender documents	14.11.2025	06.12.2025;1800 Hrs

For more details please visit <https://www.bharat-electronictender.com> and
Tata Power website <https://www.tatapower-ddl.com>.
HoD – Power Management Group
Tata Power-Delhi Distribution Limited, Technology Centre- 110034



INDOCO REMEDIES LIMITED
Regd Office : Indoco House, 166 C.S.T. Road, Santacruz (East), Mumbai 400098. **CIN No.** L85190MH1947PLC005913,
Website : www.indoco.com **E-Mail** : ajayk@indoco.com,
Phone No. (91-22) 6287 1000 / 6879 1250

Public Notice
(Under paragraph 21(2) of the Drugs Price Control Order, 2013)
Attention of general public is drawn to the fact that Indoco Remedies Limited having registered office at aforesaid address is manufacturing / marketing scheduled formulation namely Metckek SR 500 with Metformin 500mg & Metckek SR 1000 with Metformin 1000mg; (hereinafter referred to as medicine). Indoco Remedies Limited wants to discontinue and stop the manufacture / marketing of the above said products after a period of six / twelve months from the date of this notice.
After discontinuation of the above medicine, the same may not be available in the market. Therefore, patients using such medicine may consult their doctor for prescribing alternate medicine. All the doctors/Medical Personnels may also make note of this.
For Indoco Remedies Limited
sd/-
Ajay S. Karajagi
President – Sales & Mktg.
Place : Mumbai
Date : 14.11.2025

AEROGRID ADVANCED HOSTING SOLUTIONS PRIVATE LIMITED
(Earlier known as "Alotronix Warehousing Fourteen Private Limited")
Corporate Identification Number: U70200MH2024PTC418088
Registered Office: Tower 1, 15th Floor, 1501 B, One World Centre, Senapati Bapat Marg, Delisle Road, Mumbai, Maharashtra, India - 400013
Website: www.aerogrid.in | **Telephone:** +022-62805000 | **E-mail:** compliance@southcitymall.in

Unaudited Financial Results for the quarter and half year ended September 30, 2025

The Board of Directors of Aerogrid Advanced Hosting Solutions Private Limited (*Earlier known as "Alotronix Warehousing Fourteen Private Limited"*) at its meeting held on November 13, 2025, have approved the unaudited standalone financial results of the Company for the quarter and half year ended September 30, 2025 ("**Financial Results**") pursuant to the recommendation of the Audit Committee.

The full format of the Financial Results, including the line items referred to under Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are available on the websites of BSE Limited at <https://www.bseindia.com/> and Company at <https://aerogrid.in/results-publications> and can also be accessed by scanning the following Quick Response Code:



Thanking you,
For and on behalf of Aerogrid Advanced Hosting Solutions Private Limited
(*Earlier known as "Alotronix Warehousing Fourteen Private Limited"*)

Sd/-
Srejan Goyal
Director
DIN: 09292309

Date: November 13, 2025
Place: Mumbai

XTGLOBAL INFOTECH LIMITED
CIN : L72200TG1986PLC006644
Plot No 31P and 32, Tower A, Ramky Selenium, Financial District, Nanakramguda, Hyderabad, Telangana – 500032
E-mail- company.secretary@xtglobal.com, Tel: 040-66353456 Website: xtglobal.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2025
Rs. In Lakhs

S No.	PARTICULARS	STANDALONE			CONSOLIDATED		
		QUARTER ENDED	HALF YEAR ENDED	YEAR ENDED	QUARTER ENDED	HALF YEAR ENDED	YEAR ENDED
		30-09-2025	30-09-2025	31-03-2025	30-09-2025	30-09-2025	31-03-2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total Income from Operations	1,798.55	3,575.91	7,171.24	9,441.16	18,671.72	23,413.92
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items	169.14	302.26	662.68	432.51	844.20	1,330.76
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	169.14	302.26	662.68	432.51	844.20	1,330.76
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	176.42	328.57	489.43	344.14	717.68	991.16
5	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	176.42	328.57	456.59	344.14	717.68	958.31
6	Paid up Equity Share Capital	1,335.62	1,335.62	1,335.62	1,335.62	1,335.62	1,335.62
7	Reserves (excluding Revaluation Reserve)	18,305.50	18,305.50	17,839.01	17,869.62	17,869.62	16,919.30
8	Earnings Per Share (of Rs. 1/- each) (for continuing and discontinued operations) - Basic	0.13	0.25	0.34	0.20	0.42	0.66
	Diluted	0.13	0.25	0.34	0.20	0.42	0.66

NOTE : The above is an extract of the detailed format of Unaudited Quarterly/Half Yearly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Quarterly/Half Yearly Financial Results are available on the websites of the Stock Exchanges and the listed entity www.xtglobal.com



On behalf of the Board of Directors
For **XTGlobal Infotech Limited**
Sreedevi Vuppuluri
Wholetime Director
DIN: 02448540

Place : Hyderabad
Date : November 13, 2025



Regd. Office :Distillery Unit, Dabwali road Sangat Kalan, Bathinda-151401 (Pb.)
Ph. : 0164-2240163, 2240443, 2211628, Fax: 0164-5003638
Website: www.bcl.ind.in, Email: bcl@mittalgroup.co.in
CIN: L24231PB1976PLC003624

EXTRACT OF THE CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED 30TH SEPTEMBER, 2025 (RS. IN LAKHS)

PARTICULARS	CONSOLIDATED					
	Quarter Ended			Half Year Ended		F.Y. Ended
	30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
TOTAL INCOME FROM OPERATIONS	72087.78	82293.16	74840.08	154380.94	140869.82	291864.98
PROFIT BEFORE EXCEPTIONAL ITEMS AND TAX	4504.31	3775.35	3928.16	8279.66	7278.05	13659.25
PROFIT BEFORE TAX, AFTER EXCEPTIONAL ITEMS	4504.31	3775.35	3928.16	8279.66	7278.05	13659.25
NET PROFIT AFTER TAX AND EXCEPTIONAL ITEMS	3154.8	3347.93	2986.65	6502.73	5437.38	10284.90
TOTAL COMPREHENSIVE INCOME	3191.79	3347.93	3060.51	6539.72	5511.24	10359.57
PAID UP EQUITY SHARE CAPITAL (EQ. SHOF RS. 10/- EACH)	2951.63	2951.63	2951.63	2951.63	2951.63	2951.63
OTHER EQUITY	82441.79	80270.2	72738.48	82441.79	72738.48	77207.07
EARNINGS PER SHARE (of Rs. 1/- each) (not annualised):						
(a) Basic (Rs.)	0.98	1.04	0.94	2.02	1.75	3.26
(b) Diluted (Rs.)	0.98	1.04	0.94	2.02	1.75	3.26

The abstract of the Standalone Unaudited Financial Results for Quarter ended 30th SEPTEMBER, 2025 is as given below:

Total Revenue from Operations	47767.65	59071.28	53300.08	106838.93	100762.37	207416.29
Net Profit before Tax, Exceptional and/or Extraordinary items#)	2936.46	2452.42	2759.67	5388.88	5099.84	9444.47
Net Profit after Exceptional and/or Extraordinary items#)	2936.46	2452.42	2759.67	5388.88	5099.84	9444.47
Total Comprehensive Income for the period (after tax)]	2116.51	2229.75	2101.59	4346.26	3797.68	7151.66

The above is an extract of the detailed format of Consolidated/ Standalone Unaudited Quarterly Financial Results filed with the Stock Exchanges (BSE & NSE) under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of Unaudited Consolidated and Standalone Financial Results are available on the websites of the BSE and NSE (Stock Exchanges) i.e. www.bseindia.com and www.nseindia.com and on Company's website i.e. www.bcl.ind.in

For and on behalf of the Board of Directors

Sd/-
Rajinder Mittal
(Managing Director)

Place:Bathinda (Punjab)
Date : 12/11/2025



KOPRAN LIMITED
CIN : L24230MH1958LC011078
Parijat House, 1076, Dr. E. Moses Road, Worli, Mumbai - 400 018.
Website: www.kopran.com, Email Id: investors@kopran.com, Tel. No.: 022-43661111



EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025
(Rs. In Lakhs)

PARTICULARS	Quarter ended 30.09.2025	Half Year ended 30.09.2025	Quarter ended 30.09.2024	Year ended 31.03.2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total Income from operation (net)	11,790.93	25,312.55	15,156.19	62,960.44
Profit/(Loss) for the period from ordinary activities before tax	(1,162.63)	(173.72)	964.46	5,194.86
Net Profit/(Loss) for the period from ordinary activities after tax	(992.32)	(247.39)	738.41	3,855.19
Total Comprehensive Income /(Loss) for the period after tax	(1,003.05)	(281.37)	742.59	3,775.70
Equity Share Capital (Face Value of Rs 10/- per share)	4,828.56	4,828.56	4,821.06	4,828.56
Reserve (excluding Revaluation Reserve as per balance sheet)		45,279.72		47,006.23
Earnings Per Share (of Rs. 10/- each)				
Basic:	(2.06)	(0.51)	1.53	7.99
Diluted:	(2.06)	(0.51)	2.30	7.99

Note:
(1) The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Disclosure Requirement) Regulation, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange website (www.nseindia.com and www.bseindia.com), and on the Company's website www.kopran.com.
(2) The above Statement of consolidated and standalone unaudited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act 2013, read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India. There is no minority interest.
(3) The above Statement of consolidated and standalone unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 12, 2025 and have been reviewed by the Statutory Auditors of the Company who have expressed unmodified conclusion.



FOR KOPRAN LIMITED
Surendra Soman
Executive Vice Chairman
DIN: 00600860

Place : Mumbai
Dated : November 12, 2025

INDOKEM LIMITED
CIN NO. : L31300MH1964PLC013088
Regd. Office: Khatau House, Plot No. 410, Mogul Lane, Mahim, Mumbai 400 016. Tel No.: +91-22-61236767/61236711
Email: iksecretarial@gmail.com Website: www.indokem.co.in

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025
(Rs. In Lakhs)

Particulars	Quarter ended September 30, 2025	June 30, 2025	September 30, 2024	Quarter ended September 30, 2025	Half Year ended September 30, 2024	Year ended March 31, 2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Total income from operations	4,084	4,174	4,334	8,258	8,033	17,881
2 Profit / (Loss) before tax	42	70	(2)	112	(141)	329
3 Profit / (Loss) for the period	41	70	(1)	111	(140)	314
4 Total comprehensive income / (loss) net of tax	34	67	(10)	101	(157)	298
5 Paid-up equity share capital (face value of Rs. 10/- each)	2,789	2,789	2,789	2,789	2,789	2,789
6 Other Equity (Excluding Revaluation Reserves)						1,404
7 Earnings per share (EPS) (not annualised)						
Total Earnings per share						
(a) Basic (in Rs.)	0.15	0.25	0.00	0.40	-0.49	1.14
(b) Diluted (in Rs.)	0.15	0.25	0.00	0.40	-0.49	1.14

Notes
1. The above is an extract of the detailed format of Quarterly/ Half Yearly Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/ Half Yearly Financial Results are available on the Stock Exchange website. (www.bseindia.com) and on the Company's website (www.indokem.co.in)
2. Key standalone financial information is given below:

Particulars	Quarter ended September 30, 2025	June 30, 2025	September 30, 2024	Quarter ended September 30, 2025	Half Year ended September 30, 2024	Year ended March 31, 2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total income from operations	3,594	3,646	3,645	7,240	6,850	15,430
Profit / (Loss) before tax	66	33	(72)	99	(253)	90
Profit / (Loss) for the period	66	33	(71)	99	(252)	91
Total comprehensive income / (loss) net of tax	62	30	(80)	92	(269)	77



By order of the Board of Directors
For Indokem Limited
Sd/-
Mahendra K. Khatau
Chairman & Managing Director
DIN: 00062794

Place : Mumbai
Date : November 13, 2025



Alkem Laboratories Limited
Regd. Office : Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai 400 013
Tel No: +91 22 3982 9999 Fax No: +91 22 2492 7190 Email Id : investors@alkem.com
CIN: L00305MH1973PLC174201

Extract of Consolidated Financial Results for the Quarter and Six months ended 30 September 2025
(₹ in Million except per share data)

Sr. No.	Particulars	Quarter ended 30.09.2025	Six months ended 30.09.2025	Quarter ended 30.09.2024	Year ended 31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total Income from Operations	40,009.9	73,721.3	34,146.7	1,29,645.2
2	Net Profit for the period (before tax and exceptional items)	8,958.3	16,539.1	7,802.6	25,270.3
3	Net Profit for the period before tax (after exceptional items)	8,958.3	16,668.4	7,802.6	25,270.3
4	Net Profit for the period after tax (after exceptional items) attributable to the owners of the Company	7,650.6	14,293.2	6,886.4	21,654.8
5	Total Comprehensive Income for the period attributable to the owners of the Company	8,083.0	14,748.7	6,954.9	21,862.3
6	Paid-up equity Share Capital (Face Value per Share: ₹ 2)	239.1	239.1	239.1	239.1
7	Other Equity				1,19,609.6
8	Earnings Per Share (not annualised for the periods)				
	a Basic (in ₹) :	63.99	119.55	57.60	181.11
	b Diluted (in ₹) :	63.99	119.55	57.60	181.11

Notes:
1. Key numbers of Standalone Financial Results

a. Total Income from continuing Operations	25,420.3	49,142.0	23,547.2	88,134.4
b. Profit before Tax from continuing operations	8,007.1	14,803.8	6,820.0	23,035.4
c. Profit After Tax from continuing operations	7,236.6	13,459.2	6,418.5	20,897.2
d. Profit before Tax from discontinued operations	969.5	1,490.5	856.7	2,938.5
e. Profit After Tax from discontinued operations	630.7	969.7	557.3	1,911.7

2 The above consolidated financial results of the Group were reviewed and recommended by the Audit Committee on 12 November 2025 and subsequently approved by the Board of Directors at its meeting held on 13 September 2025. The auditors have issued an unmodified review report on the financial results for the quarter and six months ended 30 September 2025.

3 Financial results for the periods presented have been prepared in accordance with Indian Accounting standards ('Ind AS') notified by the Ministry of Corporate Affairs in consultation with the National Advisory Committee on Accounting Standards, under section 133 of the Companies Act, 2013 ('Act') read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and the relevant provisions of the Act.

4 The above is an extract of the detailed format of Quarterly/Year ended Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Year ended Financial Results are available on the Stock Exchange websites viz. www.bseindia.com and www.nseindia.com. The same is also available on the company website viz. www.alkemlabs.com. The same can be accessed by scanning the QR code provided below.



By Order of the Board
For Alkem Laboratories Limited

B. N. Singh
Executive Chairman
DIN: 00760310

Place: Mumbai
Date: 13 November 2025